Keywords: Germany, Drug R&D, Cancer, Diabetes, Vaccines, VFA
German pharma developing drugs against 31 forms of cancer
Article | 8 February 2010
Cancer is the top priority for Germany’s research-based pharmaceutical companies. In the last few years they have launched several treatments that have prolonged the lives of patients with intestinal, breast and various other forms of cancer. Around a third of research projects are dedicated to the development of new cancer therapies.
“ Enjoying this artcle? To continue reading you need to login, take a FREE trial or subscribe.
30 day FREE trial
Sign up in less than 60 seconds! No payment needed.
Want to read the full article?
Take a 30 day FREE Trial
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Transgene signs billion dollar deal with Novartis for TG4010 cancer vaccine option, but still disappoints investors
- US FDA issues complete response on Amgen’s Prolia with July action date
- FDA and European Medicines Agency agree to accept a single orphan drug designation annual report
- Abbott Labs bids $722 for Facet to enhances its biotech R&D pipeline, including daclizumab
- Japanese Pharma market seeing more foreign entrants
